Industries > Pharma > Global Rheumatoid Arthritis Drugs Market Forecast 2019-2029

Global Rheumatoid Arthritis Drugs Market Forecast 2019-2029

Biologics, Non-Biologics, NSAIDs, sDMARDs and Others

PUBLISHED: 17 December 2018
PAGES: 232
PRODUCT CODE: PHA0345
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: PHA0345 Categories: , Tags: , , ,

The global rheumatoid arthritis drugs market will reach $47bn in 2024. In 2018, the Biologics submarket held 87% of the Global Rheumatoid Arthritis drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 232-page report you will receive 234 charts– all unavailable elsewhere.

The 232-page report provides clear detailed insight into the rheumatoid arthritis market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Rheumatoid Arthritis Market from 2019-2029

• Forecast of the Global Rheumatoid Arthritis market by Submarket:
• Biologics
• Non-Biologics: NSAIDs, sDMARDs and Others

• Forecast of the leading drugs in the Global Rheumatoid Arthritis market:
• Humira
• Enbrel
• Remicade
• Rituxan/MabThera
• Simponi/Simponi Aria
• Orencia
• Actemra/Roactemra
• Cimzia
• Celebrex
• Xeljanz
• Arcoxia
• Others

Global Rheumatoid Arthritis Drugs Market Forecast 2019-2029

• This report provides individual revenue forecasts to 2029 for these regional and national markets:
• North America: US, Canada
• Europe: Germany, France, United Kingdom, Italy, Spain, Russia and rest of Europe
• Asia-Pacific: Japan, China, India and rest of Asia-Pacific
• Latin America: Brazil, Mexico, Rest of Latin America
• Middle East & Africa: Saudi Arabia, South Africa, Rest of MEA

Each regional market is further segmented into Biologics, Non-Biologics, NSAIDs, sDMARDs and Others

• Our study discusses the selected leading companies that are the major players in the rheumatoid arthritis market:
• AbbVie
• Amgen
• AstraZeneca
• BMS
• Eli Lilly
• Johnson & Johnson
• Merck & Co
• Novartis
• Pfizer
• Roche
• Sanofi
• UCB

• Our study discusses selected compounds under development for rheumatoid arthritis.

• This study provides a SWOT and STEP analysis of the rheumatoid arthritis drugs market.

Visiongain’s study is intended for anyone requiring commercial analyses for the rheumatoid arthritis market. You find data, trends and predictions.

Buy our report today Global Rheumatoid Arthritis Drugs Market Forecast 2019-2029: Biologics, Non-Biologics, NSAIDs, sDMARDs and Others

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Rheumatoid Arthritis Drugs Market Forecast 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Global Rheumatoid Arthritis Drugs Market Forecast 2019-2029


Latest Pharma news

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

READ

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

READ

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

READ

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

READ

Categories

Category